You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Catarina Leitão
 -- 4105 2022-05-26 17:52:52 |
2 format correction
Dean Liu
 Meta information modification 4105 2022-05-30 08:33:14 | |
3 format correction
Dean Liu
 -1 word(s) 4104 2022-05-31 02:53:58 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Leitão, C.; Matos, B.; Roque, F.; Herdeiro, M.T.; Fardilha, M. The Impact of Lifestyle on Prostate Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/23448 (accessed on 20 July 2025).
Leitão C, Matos B, Roque F, Herdeiro MT, Fardilha M. The Impact of Lifestyle on Prostate Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/23448. Accessed July 20, 2025.
Leitão, Catarina, Bárbara Matos, Fátima Roque, Maria Teresa Herdeiro, Margarida Fardilha. "The Impact of Lifestyle on Prostate Cancer" Encyclopedia, https://encyclopedia.pub/entry/23448 (accessed July 20, 2025).
Leitão, C., Matos, B., Roque, F., Herdeiro, M.T., & Fardilha, M. (2022, May 26). The Impact of Lifestyle on Prostate Cancer. In Encyclopedia. https://encyclopedia.pub/entry/23448
Leitão, Catarina, et al. "The Impact of Lifestyle on Prostate Cancer." Encyclopedia. Web. 26 May, 2022.
The Impact of Lifestyle on Prostate Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11102925

Prostate cancer (PCa) is one of the most common cancers among men, and its incidence has been rising through the years. Several risk factors have been associated with this disease and unhealthy lifestyles and inflammation were appointed as major contributors for PCa development, progression, and severity. Despite the advantages associated with the currently used diagnostic tools [prostate-specific antigen(PSA) serum levels and digital rectal examination (DRE)], the development of effective approaches for PCa diagnosis is still necessary. Finding lifestyle-associated proteins that may predict the development of PCa seems to be a promising strategy to improve PCa diagnosis.

prostate cancer lifestyle patterns inflammation

1. Introduction

Prostate cancer (PCa) is the 2nd most common (14.1%) and 5th deadliest (6.8%) cancer among men all over the world [1]. In 2020, the number of PCa cases was above 1.4 million, with a higher incidence in Europe, Asia, and Northern America. Moreover, the number of deaths exceeds 350,000, the highest mortality rate in Asia, Europe and Latin America, and the Caribbean [1]. In Portugal, PCa represents 20% of the estimated new cancer cases and 10.5% of the cancer-associated mortality [1]. Although PCa incidence has increased in recent years, a good prognosis is presented for many PCa patients [2].
The exact aetiology of PCa is difficult to determine, but several risk factors have been described. The major risk factor for PCa is the patients’ age, as most of the cases are diagnosed in men over the age of 50 [3]. The ageing-associated chronic inflammation seems to contribute to the increased PCa risk and underlies at least 20% of all human cancers [4]. Other known risk factors include family history of the disease [3], genetic alterations [5], high serum levels of insulin-like growth factor 1 (IGF-1) [5], and black ethnicity [6]. In contrast, several studies associated a healthy lifestyle with a decline in the incidence, development, and severity of PCa [7][8][9]. A healthy lifestyle, represented by the Mediterranean diet (MedDiet) and regular physical activity [9][10][11], has been associated with improved survival and decreased PCa progression [12][13]. The use of some medicines (5-α reductase (5-AR) inhibitors [14][15], nonsteroidal anti-inflammatory drugs (NSAIDs) [16], and statins [17]) was also associated with improved survival [12][13]. In contrast, dairy products with higher calcium content, alcohol consumption, smoking, sexually transmitted diseases (STDs) [13][18][19][20], higher waist circumference associated with abdominal obesity, weight gain, higher body mass index (BMI) [21][22][23], hypercholesterolaemia [24][25], hypertriglyceridaemia [26], and prostatitis [18][27] were positively correlated with the risk of advanced PCa.

2. Impact of Lifestyle on PCa Development

As there is high variability in the incidence of PCa between races, genetic variations and polymorphisms were believed to be the only risk factors associated with this disease. However, when Japanese men emigrated to Western countries, it was revealed that they had higher incidences of PCa compared with those that remained in Japan [28][29]. This suggests that other factors contribute to PCa development. In addition to innate factors, environmental factors, such as differences in eating habits, increased BMI, and obesity, have also been strongly associated with PCa [30].

2.1. Eating Habits

The Western diet is characterised by high intakes of red meat, processed foods, ‘‘fast-foods’’, high-fat dairy products, snacks, and sugary soft drinks, and low intakes of fruits, vegetables, vitamins, and minerals [31]. This type of diet is often associated with a high incidence of PCa, as well as an increased propensity to severe stages of the disease [32][33]. Furthermore, red and processed meat have been positively linked with a higher incidence and mortality from many types of cancer, including PCa [34][35].
Carbohydrates are macronutrients that provide glucose to the body, which is converted into energy, that is used to support body functions [36]. Although they are necessary for a healthy diet, the source of carbohydrates can vary. The healthiest sources of carbohydrates are unprocessed or minimally processed grains, vegetables, fruits, and beans [36]. These promote good health by delivering vitamins, minerals, and fibres. On the other hand, unhealthier sources of carbohydrates include white bread, pastries, soft drinks, and highly processed or refined foods [36]. These contain easily digested carbohydrates that contribute to weight gain, interfere with weight loss, and promote diabetes and heart diseases. Different studies [37][38] have evaluated the hypothesis that reducing these macronutrients may slow PCa development, by decreasing serum insulin or altering insulin-like growth factor (IGF). IGF is responsible for mitogenic and antiapoptotic effects on prostate epithelial cells. In castrated mice that mimic advanced stages of PCa, a low-carbohydrate diet reduced prostate tumour growth, compared to a Western diet [39][40]. Clinical studies with PCa patients also confirmed these findings, demonstrating that a high intake of refined carbohydrates was associated with an increased PCa risk [32][40] and that a low-carbohydrate, high-protein diet was associated with a lower PCa incidence [41].
This is not observed when a Mediterranean diet (MedDiet) is followed. Unlike the Western diet pattern, the MedDiet is characterised by a decreased consumption of saturated animal fat (no more than 8% of total caloric intake) and red meat, and a higher intake of plant-based foods (fruits, vegetables, bread, other cereals, potatoes, beans, nuts, and seeds). Olive oil is the main source of fat and dairy products such as yoghurt and light cheese; fish and poultry may be consumed in low-to-moderate amounts and egg consumption is restricted to four units per week [42]. This type of diet has been frequently linked to a significantly lower risk of overall malignancies, especially colorectal cancer, pharyngeal and oesophageal cancer, and PCa. This protective effect is accomplished because the whole food pattern can suppress spontaneous mutations, regulate cell proliferation mechanisms, methylation of DNA, and apoptosis [42]. Furthermore, a meta-analysis evaluated the role of tomatoes and lycopene (a component of tomatoes) in PCa [43]. The authors found that tomato products may reduce the risk of developing PCa because lycopene exerts antioxidant properties in downregulating mechanisms involved in the inflammatory response [43]. Moreover, olive oil exerts its beneficial effects due to its content of monounsaturated fatty acids, mainly oleic acid, and phenolic antioxidants such as phenols and flavonoids. Vegetables and fruits also have a high content of flavonoids, which are known for their antioxidant activity, and anti-mutagenic and anti-proliferative properties [42]. Omega-3 polyunsaturated fatty acids (PUFAs), which are present in fish and nuts, have also demonstrated a protective effect against PCa, by delaying tumour development and progression [44].

2.2. Physical Activity

Physical activity (PA) has been identified as beneficial in reducing the risk of several diseases, especially cardiovascular, musculoskeletal, pulmonary, and neurological [45]. However, regarding PCa, the topic is still under debate. A review of 83 studies conducted between 1996 and 2016 reported contradictory results. While 7 of them showed an increased incidence of PCa with PA, 31 found no association, and 45 studies demonstrated a trend or significant risk reduction of up to 30% [46]. Despite these conflicting results, regular PA appears to play a beneficial role in PCa, by preventing disease development and progression, and improving treatment outcomes. The contradictory results might be explained by the existence of different types of exercise training and intensity variation across studies.
In a prospective cohort study [47], a strong inverse association was observed between walking pace after diagnosis and the risk of PCa progression. Indeed, men who walked briskly for 3 or more hours/week had the lowest risk of progression. There was also a tendency for an inverse connection with intense activity, but the clinical sample was not significant. Brisk walking may affect PCa progression by reducing insulin resistance, decreasing bioavailable IGF-1, and increasing adiponectin levels. A role of circulating levels of insulin, bioavailable IGF-1, and adiponectin in PCa cell proliferation and apoptosis in vitro [48][49][50] and in vivo [48] has been suggested and associated with a higher risk of advanced PCa [51][52]. In another prospective cohort study [53], it was reported that men diagnosed with stage II-IV PCa, who survived at least two years after PCa diagnosis, and who became more physically active postdiagnosis or performed more recreational PA before and after diagnosis, survived longer. Furthermore, PA was also advised for patients to alleviate treatment-related side effects and improve quality of life, especially for patients receiving ADT [54][55]. Men with localised PCa who performed exercise training, such as walking/bicycling over 20 min/day, household work over 1 h/day, or exercising over 1 h/week, were associated with lower overall mortality rates. In addition, a longer time spent walking or bicycling was also reported to decrease PCa-specific mortality rates [56].

2.3. Alcohol Consumption

Alcohol consumption is considered one of the most addictive behaviours and has been reported as one of the most important risk factors for human cancers [57][58][59][60]. In colorectal cancer, heavy alcohol consumption was positively associated with increased risk, compared with light-to-moderate drinking in a meta-analysis of 16 cohort studies [61]. However, when it comes to PCa, the effect of alcohol consumption shows conflicting results.
A meta-analysis, from 2000, reported no association between alcohol consumption and PCa development [62], but in subsequent studies, increased PCa risk was related to higher levels of alcohol consumption [63][64][65]. In recent years, diverse meta-analyses have found that there is a strong relationship between the amount of alcohol consumed and PCa risk and mortality [58][66]. Moreover, heavier drinking and heavier alcohol exposure earlier in life were shown to be associated with an increased risk of high-grade disease, but had no association with low-grade PCa risk [67][68]. Red wine has been associated with a reduction of PCa risk, especially in more aggressive forms of the disease [69][70]. Despite inconsistent results, there is a tendency to associate alcohol consumption and earlier life exposures with higher PCa risk.

2.4. Smoking

Aside from alcohol, smoking is one of the most common additive behaviours and it is a well-established cause of lung cancer. Smoking is also a risk factor for other cancers, including bladder, kidney, gastrointestinal tract, and cervical cancers [71][72][73].
Regarding PCa, while recent reviews have reported no association between tobacco smoking and PCa incidence [74][75], the same did not happen with PCa mortality. Indeed, tobacco smoking could potentially play a role in PCa progression [75]. However, as with alcohol consumption, the results are contradictory. In PCa studies, smoking assessment is difficult, as they vary from smoking status at interview [76][77][78] to age at smoking onset [77][79], total consumption time [78][79], number of cigarettes [76][77], years since smoking cessation [77][80], and smoking index (pack/years) [78][79][80]. The last one is considered the gold standard for smoking assessment. Yet, it still provides inconsistent results, as the frequency, duration, and intensity of smoking may vary throughout life [81]. Cigarette smoking has been correlated with aggressive and advanced PCa in non-African American men, and there is increasing evidence that smokers have worse treatment responses [82]. Several cohort studies indicated that smokers are at lower risk for a PCa diagnosis [83][84][85][86], while other studies showed the opposite results [87][88][89][90]. Smoking was also associated with more advanced tumour stages and more aggressive baseline disease characteristics [77][85][91][92][93]. Still, further studies are needed to understand the specific role of smoking on PCa.

2.5. Use of Medication

Multiple medications have been studied for their role in PCa primary prevention, such as proton pump inhibitors (PPIs) [94], statins and NSAIDs [95], and secondary prevention, such as 5-AR inhibitors [96] and alpha-blockers [97].

2.5.1. Primary Prevention

PPIs are known to inhibit acid secretion and were originally developed to inhibit the extrusion of protons through H+/K+ ATPases in stomach cells [98][99]. They have also been associated with a reduction in Vacuolar-type H+ ATPase (V-ATPase) activity [94]. This reduced activity has been shown to have an anticarcinogenic effect in breast cancer [100], PCa [101], and melanoma [102]. However, recent studies have not demonstrated a chemopreventive effect of PPIs in PCa [94][103].
Statins are mainly used to correct lipid profiles and reduce cardiovascular morbidity and mortality [104]. Furthermore, statins may also have a chemopreventive role in cancer, by limiting cancer cells proliferation, through decreasing cholesterol availability [95]. Recent studies have confirmed the chemoprotective effect of statins, and an association with decreased PCa progression and mortality has also been described [95][105][106].
NSAIDs are a family of drugs used for their analgesic and antipyretic properties, ultimately inhibiting inflammation. The well-recognised target of these drugs is the cyclooxygenase enzyme activity of both COX-1 and COX-2 receptors [107][108][109]. As chronic inflammation has been described as one of the potential risk factors for PCa, it is important to avoid its development. Therefore, aspirin and NSAIDs have been suspected to have a preventive effect against PCa. However, the evidence is limited and still controversial. A population-based cohort study from 2017 [109] suggests that there is a decreased risk of PCa in patients treated with aspirin and NSAIDs, mainly when taken over a longer period. An EPICAP (EPIdemiology of Prostate CAncer) study from 2017 [107] also found a negative association between NSAIDs use and PCa incidence, reporting a 23% reduction in PCa risk. This effect was also assured at higher doses and exposure. A meta-analysis from 2018 [110] confirmed these results and demonstrated that NSAIDs and aspirin have a protective effect on PCa development, especially with longer exposures.

2.5.2. Secondary Prevention

5-AR inhibitors are usually used to treat benign prostatic hyperplasia (BPH) and they include finasteride and dutasteride [96]. The use of these type of medicines prevents the intraprostatic conversion of testosterone into dihydrotestosterone, which is a strong androgen. This allows the reduction of prostate volume and improvement of urinary outflow obstruction. Moreover, 5-AR inhibitors can reduce PSA levels by approximately 50% [111]. However, if PCa has not yet been diagnosed, taking this medicine may result in a delayed diagnosis, which may worsen the PCa outcome. Apart from this single recognised limitation, 5-AR inhibitors are suggested to be beneficial in preventing PCa development and progression [112][113][114].
Alpha-blockers are clinically used for hypertension and BPH, and they target α-adrenoreceptors. The most common α1-adrenoreceptor is present in the smooth muscle cells of the prostate gland and bladder neck. This type of receptor is responsible for decreasing smooth muscle tone and relieving bladder obstruction secondary to periurethral prostatic enlargement [97][115][116]. The α1-blocker quinazoline has been associated with anticancer activities, by preventing tumourigenesis, as well as mitigating progression to metastatic disease, by targeting anoikis and angiogenesis [97]. Moreover, prazosin, a quinazoline-based drug, in high doses can significantly reduce the risk of PCa recurrence and delay the time to biochemical relapse in PCa patients following radiotherapy [117].

2.6. Sexual Behaviour and STDs

There is evidence that STDs and sexual behaviour, including the number of sexual partners, age at first sexual intercourse, and frequency of sex intercourse, influence the risk of developing PCa [13][18][19][20][118].
In a 2014 study, while the age at which men had their first intercourse did not display an increased risk of PCa, the number of sexual partners (female and male) led to different results [20]. Men who were with more than 20 female sexual partners had decreased PCa risk, whereas a higher number of male sexual partners increase it [20]. This suggests that PCa risk is higher for bisexual and homosexual men. Similar conclusions have been reported regarding STDs [119][120]. However, some studies report a beneficial role of more frequent ejaculation in adulthood, particularly for low-risk PCa [13][121][122].
A meta-analysis examined the association of Neisseria gonorrhoea (responsible for gonorrhoea), Treponema pallidum (syphilis), Chlamydia trachomatis (chlamydia), Trichomonas vaginalis (trichomoniasis), Ureaplasma urealyticum, Mycoplasma hominis, Herpes Simplex Virus types 1 and 2, Human Herpes Virus 8, and Cytomegalovirus with the development and progression of PCa [19]. Men infected with gonorrhoea had a 20% increased risk of developing PCa. Moreover, while syphilis presented a significant association with PCa risk, none of the other STDs demonstrated relevance for the development and progression of the disease. Other authors suggested that only gonorrhoea and the human papillomavirus (HPV) were strongly linked to PCa risk [118]. In a population-based case-control study of black men, gonorrhoea and history of prostatitis increased the odds of developing PCa. In addition, men who have or have had more than one STD have an accentuated risk of PCa, which is consistent with studies in white men [18]. These findings suggest that STDs are a robust risk factor for PCa. However, the risk associated with each specific STD is different.

3. Impact of Inflammation on PCa

One of the potential risk factors for PCa that has gained relevance is the development of chronic inflammation in the prostate. Several factors, including viral or bacterial infections, dietary factors, hormonal changes, urine reflux, or physical injuries can contribute to prostate inflammation [123][124]. Chronic inflammation has been identified as a major cause of approximately 20% of human cancers [125]. In the prostate microenvironment, it can promote alterations that facilitate cancer progression through proliferation, cell survival, evasion of immune surveillance, tissue remodelling, production of angiogenic factors, metastatic spread, and resistance to therapeutic agents [124]. In early prostate carcinogenesis, inflammation can be identified by proliferative inflammatory atrophy (PIA). This is a lesion with activated inflammatory immune cells that can invade the peripheral zone of the prostate, where most cancers occur [126]. These lesions can proliferate at a high rate, possibly in response to cellular damage caused by inflammation, upregulation of the apoptosis regulator B-cell lymphoma 2 (Bcl-2), and expression of the proto-oncogene MYC [127]. This has been identified as a precursor of PIN, which in turn is a precursor of BPH, and PCa [125].

Since inflammation has been demonstrated to be a potentially major factor in the development of PCa, the role of inflammatory markers has gained attention (Table 1). Chemokines and cytokines play a crucial role in PCa, by promoting tumour cell proliferation, epithelial-mesenchymal transition, angiogenesis, and metastasis.

Table 1 - Inflammation markers and their targeted processes in cancer [adapted from Archer M. et al [124]].

Inflammation markers

Targeted processes

Interleukin-1 (IL-1)

Proliferation, survival, therapeutic resistance

Interleukin-6 (IL-6)

Proliferation, survival, anoikis resistance, metastasis, therapeutic resistance

Interleukin-8 (IL-8)

Proliferation, survival, angiogenesis, therapeutic resistance

Interleukin-23 (IL-23)

Therapeutic resistance

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)

Anoikis resistance, metastasis, therapeutic resistance

C-C Motif Chemokine Ligand 2 (CCL-2)

Pro-tumour immunity, metastasis, therapeutic resistance

Transforming growth factor-beta (TGF-β)

Pro-tumour immunity, angiogenesis, epithelial-mesenchymal transition (EMT), metastasis, therapeutic resistance

Tumour necrosis factor-alpha (TNF-α)

Survival, EMT, anoikis resistance

However, a specific chemokine may have pro-inflammatory or anti-inflammatory effects, depending on the circumstances. For instance, the cluster of differentiation 184 (CD184) is upregulated in PCa, but one or more of its ligands (stromal cell-derived factor 1 (SDF-1) and ubiquitin) have antiapoptotic effects [128]. In a case-control study, a group of circulating inflammatory markers were identified as possible contributors to PCa pathophysiology, including chemokine (C-X3-C motif) ligand 1 (CX3CL1), interleukin-10 (IL-10), platelet-derived growth factor-BB (PDGF‐BB) (inverse associations), Chemokine (C-C motif) ligand 21 (CCL21) and Chemokine (C-C motif) ligand 11 (CCL11) (positive associations) [129].

As inflammation is influenced by numerous molecules, it is crucial to evaluate these and assess whether they can be novel biomarkers for a better understanding of PCa.

4. Identification of novel biomarkers, including lifestyle-associated biomarkers

Since PSA screening is the main diagnostic tool currently available for PCa and it has been associated with several limitations, including disease overdiagnosis and overtreatment, there is an urgent need for novel biomarkers. However, the challenges involved in the development of new ideal markers are vast. Biomarkers should be specific for the disease and should not be expressed in other tissues or tumours. Moreover, the collection method should be non-invasive, and biomarkers should be suitable for use in large-scale screening programmes. Additionally, an ideal biomarker should distinguish not only between patients, with and without PCa, but also between clinically significant tumours and other benign conditions, like BPH [130]. For the non-invasive collection, body fluids, such as seminal fluid and urine, have been suggested [131].

Two potential biomarkers have been identified, the blood-based Prostate Health Index (PHI) and urinary prostate cancer antigen 3 (PCA3). PHI combines total PSA, free PSA (fPSA), and the PSA isoform p2PSA. Men at higher risk of significant PCa have higher levels of total PSA and p2PSA and lower levels of fPSA [132]. PHI is also associated with a biopsy Gleason score above 7 and it may have a role in monitoring men on active surveillance [132]. PCA3 is a prostate-specific noncoding mRNA that is detectable in urine and it was overexpressed in PCa tissue compared to normal prostate tissue [133][134]. Unlike PSA, PCA3 expression is less influenced by the patient’s age, prostate volume, inflammation, trauma, or prior biopsies [131][134]. Both PHI and PCA3 were able to predict PCa, but studies disagreed on accuracy [135][136][137]. Moreover, both also improved the prediction of tumour stage and tumour volume [138][139].

The 4K score is a test that combines a panel of four kallikrein proteins: total PSA, fPSA, intact PSA, and human kallikrein-related peptidase 2 (hK2) [140]. It uses an algorithm that takes into account the patient’s age, DRE, and history of previous biopsies [141]. Thus, it can provide higher accuracy of individual patient’s risk of high-grade PCa, compared to the one using PSA and fPSA [142]. Since it is a more personalized test, it may prevent unnecessary biopsies and it can predict metastases up to 20 years ahead with higher precision [141][142].

A study investigated the possibility of exploring novel biomarkers through metabolic profiling of urine [143][144]. Indeed, metabolomics has been applied to different types of samples, including prostate tissue [145], cell lines [146] and serum [147], with the ultimate goal of finding novel diagnostic biomarkers. Regarding urine,  guanidinoacetate, phenylacetylglycine, and glycine were appointed as potential candidate markers for PCa since their levels could be distinguished between PCa patients and healthy subjects. Another study examined exosomes in African American men compared with Caucasian menbecause PSA screening is not as effective in African American men [148][149]. Exosomes are small vesicles that are originated from endosomes and secreted into the extracellular milieu after the fusion of multivesicular endosomes with the plasma membrane. Their potential for diagnosis and prognosis has been suggested. Filamin A [150], Vitamin D-binding protein [151], and Afamin [152] have already been studied as biomarkers in breast cancer, pancreatic cancer, and ovarian cancer, respectively, and have also been identified in exosomes from African Americans with PCa [153].

Other potential biomarkers include miRNAs, such as miR-21, miR-182, and miR-101. miR-21 is highly expressed in solid tumours, including in prostate tumours [154][155][156][157]. This miRNA reduced the expression of Programmed cell death 4 (PDCD4), a suppressor of tumourigenesis and tumour progression, by expressing IL-6 in PCa cells [158]. The miR-183-96-182 cluster was reported to be overexpressed in PCa and miR-182 promotes PCa cell proliferation and invasion by targeting multiple genes [159][160][161][162]. Hypoxia is a hallmark of PCa with a poor prognosis and it enhances the presence of bone metastases [163][164][165]. Thus, the involvement of miR-182 in hypoxia adaptation and/or angiogenesis was evaluated. Hypoxia-activated miR-182, inhibited the negative regulators of the hypoxia-inducible 1α factor (HIF-1α) signalling pathway, hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) and factor inhibiting HIF-1 (FIH-1), and increased HIF-1α signalling in PCa [166]. miR-182 could be a potential target for PCa since it encourages the irreversible activation of the HIF-1α pathway and the stable switching of the cellular state for tumour growth and angiogenesis under hypoxic conditions [166]. Finally, miRNA-101 is downregulated in PCa compared with normal tissues [167]. The ability to target COX-2 in several cancers has also been reported for miRNA-101 [168]. This miRNA was also able to inhibit COX-2 protein expression, decreasing the proliferation and growth of PCa cells in vitro and in vivo [168]. Thus, these three miRNAs may be potential biomarkers for PCa.

Several molecules, associated with lifestyle, have been used to evaluate PCa risk and the examination of dietary patterns has also been considered an appealing approach. Hyperinsulinemia and inflammation are two interrelated biological pathways that have been linked with PCa risk [169][170]. Therefore, dietary patterns that directly influence these biological pathways may be more predictive of PCa risk. A study from 2020 [171] assesses circulating biomarkers such as C-reactive protein (CRP), adiponectin, interleukin-6 (IL6), type 2 TNF-α receptor (TNFα-R2), c-peptide, and insulin. The main goal was to evaluate these biomarkers using two different indexes: i) the Empirical Dietary Index for Hyperinsulinemia (EDIH) score to assess the hyperinsulinemia potential of the diet [172] and ii) the Empirical Dietary Inflammatory Pattern (EDIP) score to confirm the inflammatory potential of the diet [173]. Both indexes’ score predicted relevant biomarker concentrations to their respective patterns of dietary insulinemic and inflammatory potential. Moreover, the EDIH predicted future PCa risk, especially for high-grade PCa, suggesting a dietary pattern for PCa prevention.

Moreover, irisin, a myokine/adipokine, synthesized in many tissues, including skeletal muscle and fat cells, and that participates in the regulation of lipid and glucose metabolism, has also been studied to be a potential lifestyle-associated biomarker in PCa. Since it regulates fat metabolism, it plays a crucial role in the arising and development of obesity, obesity-related insulin resistance, diabetes, non-alcoholic fatty liver disease, and other metabolic diseases [174][175]. In a recent prospective study, serum irisin levels were shown to be significantly lower in patients with PCa [176].In the last years, many putative biomarkers for PCa have emerged that still need robust validation.

6. Conclusion

As PCa aetiology is still under investigation, it is necessary to establish the link between inflammation and general lifestyle in the progression of PCa. By identifying this association, it would be possible to adopt preventive measures, such as different diets or different activity behaviours. This is extremely important since it could help appraise the evolution of chronic inflammation and, consequently, PCa. Studying the impact of lifestyle and inflammation on PCa may open new avenues to identify a suitable biomarker for the diagnosis or treatment follow-up of PCa. Moreover, they could complement PSA screening, and enable the identification of men at higher risk of developing a severe form of the disease, which is imperative to prevent lethal PCa. Furthermore, novel biomarkers would prevent patients from being exposed to aggressive and unnecessary treatments

References

  1. World Health Organization, WHO. Global Cancer Observatory: Cancer Today 2020. Available online: https://gco.iarc.fr/today (accessed on 20 August 2021).
  2. Wong, M.C.S.; Goggins, W.B.; Wang, H.H.X.; Fung, F.D.H.; Leung, C.; Wong, S.Y.S.; Ng, C.F.; Sung, J.J.Y. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur. Urol. 2016, 70, 862–874.
  3. Bratt, O.; Drevin, L.; Akre, O.; Garmo, H.; Stattin, P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. J. Natl. Cancer Inst. 2016, 108, djw110.
  4. De Angulo, A.; Faris, R.; Daniel, B.; Jolly, C.; DeGraffenried, L. Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells. Prostate 2015, 75, 449–462.
  5. Moran, A.; O’Hara, C.; Khan, S.; Shack, L.; Woodward, E.; Maher, E.R.; Lalloo, F.; Evans, D.G.R. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer 2012, 11, 235–242.
  6. Felgueiras, J.; Silva, J.V.; Fardilha, M. Prostate cancer: The need for biomarkers and new therapeutic targets. J. Zhejiang Univ. Sci. B 2014, 15, 16–42.
  7. Langlais, C.S.; Graff, R.E.; Blarigan ELVan Palmer, N.R.; Washington, S.L.; Chan, J.M.; Kenfield, S.A. Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. Curr. Oncol. Rep. 2021, 23, 37.
  8. Daubenmier, J.J.; Weidner, G.; Marlin, R.; Crutchfield, L.; Dunn-Emke, S.; Chi, C.; Gao, B.; Carroll, P.; Ornish, D. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 2006, 67, 125–130.
  9. Peisch, S.F.; Van Blarigan, E.L.; Chan, J.M.; Stampfer, M.J.; Kenfield, S.A. Prostate cancer progression and mortality: A review of diet and lifestyle factors. World J. Urol. 2017, 35, 867–874.
  10. Ballon-Landa, E.; Parsons, J.K. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Curr. Opin. Urol. 2018, 28, 55–61.
  11. Leitão, C.; Mignano, A.; Estrela, M.; Fardilha, M.; Figueiras, A.; Roque, F.; Herdeiro, M.T. The Effect of Nutrition on Aging—A Systematic Review Focusing on Aging-Related Biomarkers. Nutrients 2022, 14, 554.
  12. Pernar, C.H.; Ebot, E.M.; Wilson, K.M.; Mucci, L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb. Perspect. Med. 2018, 8, a030361.
  13. Rawla, P. Epidemiology of Prostate Cancer. World J. Oncol. 2019, 10, 63–89.
  14. Andriole, G.L.; Bostwick, D.G.; Brawley, O.W.; Gomella, L.G.; Marberger, M.; Montorsi, F.; Pettaway, C.A.; Tamella, T.L.; Teloken, C.; Tindall, D.J.; et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010, 362, 1192–1202.
  15. Thompson, I.M.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Miller, G.J.; Ford, L.G.; Lieber, M.M.; Cespedes, R.D.; Atkins, J.N.; Lippman, S.M.; et al. The Influence of Finasteride on the Development of Prostate Cancer. N. Engl. J. Med. 2003, 349, 1695–1702.
  16. Jafari, S.; Etminan, M.; Afshar, K. Nonsteroidal anti-inflammatory drugs and prostate cancer: A systematic review of the literature and meta-analysis. Cancer Urol. Assoc. J. 2009, 3, 323–330.
  17. Chang, S.L.; Harshman, L.C.; Presti, J.C. Impact of common medications on serum total prostate-specific antigen levels: Analysis of the National Health and Nutrition Examination Survey. J. Clin. Oncol. 2010, 28, 3951–3957.
  18. Sarma, A.V.; McLaughlin, J.C.; Wallner, L.P.; Dunn, R.L.; Cooney, K.A.; Schottenfeld, D.; Montie, J.E.; Wei, J.T. Sexual Behavior, Sexually Transmitted Diseases and Prostatitis: The Risk of Prostate Cancer in Black Men. J. Urol. 2006, 176, 1108–1113.
  19. Caini, S.; Gandini, S.; Dudas, M.; Bremer, V.; Severi, E.; Gherasim, A. Sexually transmitted infections and prostate cancer risk: A systematic review and meta-analysis. Cancer Epidemiol. 2014, 38, 329–338.
  20. Spence, A.R.; Rousseau, M.C.; Parent, M.É. Sexual partners, sexually transmitted infections, and prostate cancer risk. Cancer Epidemiol. 2014, 38, 700–707.
  21. Freedland, S.J.; Bañez, L.L.; Sun, L.L.; Fitzsimons, N.J.; Moul, J.W. Obese men have higher-grade and larger tumors: An analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009, 12, 259–263.
  22. Møller, H.; Roswall, N.; Hemelrijck, M.V.; Larsen, S.B.; Cuzick, J.; Holmberg, L.; Overvad, K.; Tjønneland, A. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark. Int. J. Cancer 2015, 136, 1940–1947.
  23. Vidal, A.C.; Howard, L.E.; Moreira, D.M.; Castro-Santamaria, R.; Andriole, G.L.; Freedland, S.J. Obesity increases the risk for high-grade prostate cancer: Results from the REDUCE study. Cancer Epidemiol. Biomark. Prev. 2014, 23, 2936–2942.
  24. Mittal, A.; Sathian, B.; Chandrasekharan, N.; Lekhi, A.; Yadav, S.K. Role of hypercholesterolemia in prostate cancer-case control study from manipal teaching hospital Pokhara, Nepal. Asian Pac. J. Cancer Prev. 2011, 12, 1905–1907.
  25. Shafique, K.; McLoone, P.; Qureshi, K.; Leung, H.; Hart, C.; Morrison, D.S. Cholesterol and the risk of grade-specific prostate cancer incidence: Evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer 2012, 12, 25.
  26. Hayashi, N.; Matsushima, M.; Yamamoto, T.; Sasaki, H.; Takahashi, H.; Egawa, S. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 2012, 109, 515–519.
  27. Jiang, J.; Li, J.; Zhang, Y.; Zhu, H.; Liu, J.; Pumill, C. The role of prostatitis in prostate cancer: Meta-analysis. PLoS ONE 2013, 8, e85179.
  28. Shimizu, H.; Ross, R.K.; Bernstein, L.; Yatani, R.; Henderson, B.E.; MAck, T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 1991, 63, 963–966.
  29. Tsugane, S.; de Souza, J.M.P.; Costa, M.L.; Mirra, A.P.; Gotlieb, S.L.D.; Laurenti, R.; Watanabe, S. Cancer incidence rates among Japanese immigrants in the city of São Paulo, Brazil, 1969–1978. Cancer Causes Control. 1990, 1, 189–193.
  30. German, J.B. Influence of diet and nutrition. Int. J. Mol. Sci. 2020, 21, 1447.
  31. Christ, A.; Lauterbach, M.; Latz, E. Western Diet and the Immune System: An Inflammatory Connection. Immunity 2019, 51, 794–811.
  32. Fabiani, R.; Minelli, L.; Bertarelli, G.; Bacci, S. A Western Dietary Pattern Increases Prostate Cancer Risk: A Systematic Review and Meta-Analysis. Nutrients 2016, 8, 626.
  33. Jalilpiran, Y.; Dianatinasab, M.; Zeighami, S.; Ghiasvand, R.; Amir, S.; Mohajeri, R.; Faghih, S. Western Dietary Pattern, But not Mediterranean Dietary Pattern, Increases the Risk of Prostate Cancer. Nutr. Cancer 2018, 70, 851–859.
  34. Ma, R.W.L.; Chapman, K. A systematic review of the effect of diet in prostate cancer prevention and treatment. J. Hum. Nutr. Diet 2009, 22, 187–199.
  35. Wang, Y.; Jacobs, E.J.; Shah, R.A.; Stevens, V.L.; Gansler, T.; McCullough, M.L. Red and processed meat, poultry, fish, and egg intakes and cause-specific and all-cause mortality among men with nonmetastatic prostate cancer in a U.S. Cohort. Cancer Epidemiol. Biomark. Prev. 2020, 29, 1029–1038.
  36. Loukou, A.L.; Gbakayoro, J.; Yves, K.; Anvoh, B.; Paule, A.; Kouame, N.; Brou, K. Consumption Frequency and Proximate Composition of Some Carbohydrate Foods Most Consumed in Abidjan (Côte d’Ivoire). J. Food Sci. Nutr. Res. 2020, 3, 252–261.
  37. Chan, J.M.; Stampfer, M.J.; Giovannucci, E.; Gann, P.H.; Ma, J.; Wilkinson, P.; Hennekens, C.H.; Pollak, M. Plasma Insulin-Like Growth Factor-l and Prostate Cancer Risk: A Prospective Study. Science 1998, 279, 563–566.
  38. Mavropoulos, J.C.; Isaacs, W.B.; Pizzo, S.V.; Freedland, S.J. Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer? Urology 2006, 68, 15–18.
  39. Fokidis, H.B.; Yieng, M.; Ho, V.W.; Adomat, H.H.; Soma, K.K.; Fazli, L.; Mun, K.; Cox, M.; Krystal, G.; Zoubeidi, A.; et al. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice. J. Steroid Biochem. Mol. Biol. 2015, 150, 35–45.
  40. Drake, I.; Sonestedt, E.; Gullberg, B.; Bjartell, A.; Wallstro, P.; Wirfa, E. Dietary intakes of carbohydrates in relation to prostate cancer risk: A prospective study in the Malmo. Am. J. Clin. Nutr. 2012, 96, 1409–1418.
  41. Ax, E.; Garmo, H.; Grundmark, B.; Bill-axelson, A.; Holmberg, L.; Becker, W.; Zethelius, B.; Cerdholm, T.; Sjögren, P. Dietary Patterns and Prostate Cancer Risk: Report from the Population Based ULSAM Cohort Study of Swedish Men Dietary Patterns and Prostate Cancer Risk: Report from the Population Based ULSAM Cohort Study of Swedish Men. Nutr. Cancer 2014, 66, 77–87.
  42. Capurso, C.; Vendemiale, G. The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review. Front. Nutr. 2017, 4, 38.
  43. Etminan, M.; Takkouche, B.; Caamaño-Isorna, F. The Role of Tomato Products and Lycopene in the Prevention of Prostate Cancer: A Meta-Analysis of Observational Studies. Cancer Epidemiol. Biomark. Prev. 2004, 13, 340–345.
  44. Berquin, I.M.; Min, Y.; Wu, R.; Wu, J.; Perry, D.; Cline, J.M.; Thomas, M.J.; Thornburg, T.; Kulik, G.; Smith, A.; et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Investig. 2007, 117, 1866–1875.
  45. Kujala, U.M. Evidence on the effects of exercise therapy in the treatment of chronic disease. Br. J. Sports Med. 2009, 43, 550–555.
  46. Shephard, R.J. Physical Activity and Prostate Cancer: An Updated Review. Sport Med. 2017, 47, 1055–1073.
  47. Richman, E.L.; Kenfield, S.A.; Stampfer, M.J.; Paciorek, A.; Carroll, P.R.; Chan, J.M. Physical activity after diagnosis and risk of prostate cancer progression: Data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011, 71, 3889–3895.
  48. Frasca, F.; Pandini, G.; Sciacca, L.; Pezzino, V.; Squatrito, S.; Belfiore, A.; Vigneri, R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 2008, 114, 23–37.
  49. Barb, D.; Williams, C.J.; Neuwirth, A.K.; Mantzoros, C.S. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am. J. Clin. Nutr. 2007, 86, 858–866.
  50. Zakikhani, M.; Dowling, R.J.O.; Sonenberg, N.; Pollak, M.N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. 2008, 1, 369–375.
  51. Li, H.; Stampfer, M.J.; Mucci, L.; Rifai, N.; Qiu, W.; Kurth, T.; Ma, J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin. Chem. 2010, 56, 34–43.
  52. Rowlands, M.A.; Gunnell, D.; Harris, R.; Vatten, L.J.; Holly, J.M.P.; Martin, R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int. J. Cancer 2009, 124, 2416–2429.
  53. Friedenreich, C.M.; Wang, Q.; Neilson, H.K.; Kopciuk, K.A.; McGregor, S.E.; Courneya, K.S. Physical Activity and Survival After Prostate Cancer. Eur. Urol. 2016, 70, 576–585.
  54. Gardner, J.R.; Livingston, P.M.; Fraser, S.F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: A systematic review. J. Clin. Oncol. 2014, 32, 335–346.
  55. Winters-Stone, K.M.; Beer, T.M. Review of exercise studies in prostate cancer survivors receiving androgen deprivation therapy calls for an aggressive research agenda to generate high-quality evidence and guidance for exercise as standard of care. J. Clin. Oncol. 2014, 32, 2518–2519.
  56. Bonn, S.E.; Sjölander, A.; Lagerros, Y.T.; Wiklund, F.; Stattin, P.; Holmberg, E.; Grönberg, H.; Bälter, K. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol. Biomark. Prev. 2015, 24, 57–64.
  57. Allen, N.E.; Beral, V.; Casabonne, D.; Kan, S.W.; Reeves, G.K.; Brown, A. Moderate Alcohol Intake and Cancer Incidence in Women. JNCI J. Natl. Cancer Inst. 2009, 101, 296–305.
  58. Bagnardi, V.; Rota, M.; Botteri, E.; Tramacere, I.; Islami, F.; Fedirko, V.; Scotti, L.; Jenab, M.; Turati, F.; Pascuali, E.; et al. Alcohol consumption and site-specific cancer risk: A comprehensive dose—response. Br. J. Cancer 2015, 112, 580–593.
  59. Jung, S.; Wang, M.; Anderson, K.; Baglietto, L.; Bergkvist, L.; Bernstein, L.; Eliassen, A.H.; Falk, R.; Gapstur, S. Alcohol consumption and breast cancer risk by estrogen receptor status: In a pooled analysis of 20 studies. Int. J. Epidemiol. 2016, 45, 916–928.
  60. Bagnardi, V.; Rota, M.; Botteri, E.; Tramacere, I.; Islami, F.; Fedirko, V.; Scotti, L.; Jenab, M.; Turati, F.; Pascuali, E.; et al. Light alcohol drinking and cancer: A meta-analysis. Ann. Oncol. 2013, 24, 301–308.
  61. Mcnabb, S.; Harrison, T.A.; Albanes, D.; Berndt, S.I.; Brenner, H.; Caan, B.J. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. Int. J. Cancer 2020, 146, 861–873.
  62. Dennis, L.K. Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate 2000, 42, 56–66.
  63. Rota, M.; Scotti, L.; Turati, F.; Tramacere, I.; Islami, F.; Bellocco, R.; Negri, E.; Corrao, G.; Boffetta, P.; La Vecchia, C.; et al. Alcohol consumption and prostate cancer risk: A meta-analysis of the dose-risk relation. Eur. J. Cancer Prev. 2012, 21, 350–359.
  64. Fillmore, K.M.; Chikritzhs, T.; Stockwell, T.; Bostrom, A.; Pascal, R. Alcohol use and prostate cancer: A meta-analysis. Mol. Nutr. Food Res. 2009, 53, 240–255.
  65. Bagnardi, V.; Blangiardo, M.; Vecchia CLa Corrao, G. A meta-analysis of alcohol drinking and cancer risk. Br. J. Cancer 2001, 85, 1700–1705.
  66. Zhao, J.; Stockwell, T.; Roemer, A.; Chikritzhs, T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer 2016, 16, 845.
  67. Zuccolo, L.; Lewis, S.J.; Donovan, J.L.; Hamdy, F.C.; Neal, D.E.; Smith, G.D. Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study. Int. J. Cancer 2013, 132, 2176–2185.
  68. Michael, J.; Howard, L.E.; Markt, S.C.; De Hoedt, A.; Bailey, C.; Mucci, L.A.; Freedland, S.J.; Allott, E.H. Early-life alcohol intake and high-grade prostate cancer: Results from an equal-access, racially diverse biopsy cohort. Cancer Prev. Res. 2018, 11, 621–628.
  69. Schoonen, W.M.; Salinas, C.A.; Kiemeney, L.A.L.M.; Stanford, J.L. Alcohol consumption and risk of prostate cancer in middle-aged men. Int. J. Cancer 2005, 113, 133–140.
  70. Larsson, S.C.; Carter, P.; Kar, S.; Vithayathil, M.; Mason, A.M.; Michaëlsson, K.; Burgess, S. Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. 2020, 17, e1003178.
  71. McGee, E.E.; Jackson, S.S.; Petrick, J.L.; Van Dyke, A.L.; Adami, H.O.; Albanes, D.; Andreotti, G.; Beane-Freeman, L.E.; Berrington de Gonzalez, A.; Buring, J.E.; et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J. Natl. Cancer Inst. 2019, 111, 1263–1278.
  72. Pirie, K.; Peto, R.; Reeves, G.K.; Green, J.; Beral, V. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. Lancet 2013, 381, 133–141.
  73. Gandini, S.; Botteri, E.; Iodice, S.; Boniol, M.; Lowenfels, A.B.; Maisonneuve, P.; Boyle, P. Tobacco smoking and cancer: A meta-analysis. Int. J. Cancer 2008, 122, 155–164.
  74. Huncharek, M.; Sue Haddock, K.; Reid, R.; Kupelnick, B. Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies. Am. J. Public Health 2010, 100, 693–701.
  75. Islami, F.; Moreira, D.M.; Boffetta, P.; Freedland, S.J. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur. Urol. 2014, 66, 1054–1064.
  76. Murphy, A.B.; Akereyeni, F.; Nyame, Y.A.; Guy, M.C.; Martin, I.K.; Hollowell, C.M.P.; Walker, K.; Kittles, R.A.; Ahaghotu, C. Smoking and prostate cancer in a multi-ethnic cohort. Prostate 2013, 73, 1518–1528.
  77. Rohrmann, S.; Linseisen, J.; Allen, N.; Bueno-De-Mesquita, H.B.; Johnsen, N.F.; Tjønneland, A.; Overvad, K.; Kaaks, R.; Teucher, B.; Boeing, H.; et al. Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br. J. Cancer 2013, 108, 708–714.
  78. Bae, J.M.; Li, Z.M.; Shin, M.H.; Kim, D.H.; Lee, M.S.; Ahn, Y.O. Cigarette smoking and prostate cancer risk: Negative results of the Seoul male cancer cohort study. Asian Pac. J. Cancer Prev. 2013, 14, 4667–4669.
  79. Giles, G.G.; Severi, G.; McCredie, M.R.E.; English, D.R.; Johnson, W.; Hopper, J.L.; Boyle, P. Smoking and prostate cancer: Findings from an Australian case-control study. Ann. Oncol. 2001, 12, 761–765.
  80. Plaskon, L.A.; Penson, D.F.; Vaughan, T.L.; Stanfordz, J.L. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol. Biomark. Prev. 2003, 12, 604–609.
  81. Jiménez-Mendoza, E.; Vázquez-Salas, R.A.; Barrientos-Gutierrez, T.; Reynales-Shigematsu, L.M.; Labra-Salgado, I.R.; Manzanilla-García, H.A.; Torres-Sánchez, L.E. Smoking and prostate cancer: A life course analysis. BMC Cancer 2018, 18, 160.
  82. Brookman-May, S.D.; Campi, R.; Henríquez, J.D.S.; Klatte, T.; Langenhuijsen, J.F.; Brausi, M.; Linares-Espinós, E.; Volpe, A.; Marszalek, M.; Akdogan, B.; et al. Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). Eur. Urol. Focus 2019, 5, 756–787.
  83. Karlsen, R.V.; Bidstrup, P.E.; Christensen, J.; Larsen, S.B.; Tjønneland, A.; Dalton, S.O.; Johansen, C. Men with cancer change their health behaviour: A prospective study from the Danish Diet, Cancer and Health Study. Br. J. Cancer 2012, 107, 201–206.
  84. Butler, L.M.; Wang, R.; Wong, A.S.; Koh, W.P.; Yu, M.C. Cigarette smoking and risk of prostate cancer among Singapore Chinese. Cancer Causes Control. 2009, 20, 1967–1974.
  85. Rohrmann, S.; Genkinger, J.M.; Burke, A.; Helzlsouer, K.J.; Comstock, G.W.; Alberg, A.J.; Platz, E.A. Smoking and Risk of Fatal Prostate Cancer in a Prospective U.S. Study. Urology 2007, 69, 721–725.
  86. Giovannucci, E.; Liu, Y.; Platz, E.A.; Stampfer, M.J.; Willett, W.C. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int. J. Cancer 2007, 121, 1571–1578.
  87. Tang, B.; Han, C.T.; Gan, H.L.; Zhang, G.M.; Zhang, C.Z.; Yang, W.Y.; Shen, Y.; Zhu, Y.; Ye, D.W. Smoking increased the risk of prostate cancer with grade group ≥ 4 and intraductal carcinoma in a prospective biopsy cohort. Prostate 2017, 77, 984–989.
  88. Lassed, S.; Deus, C.M.; Lourenço, N.; Dahdouh, A.; Rizvanov, A.A.; Oliveira, P.J.; Zama, D. Diet, Lifestyles, Family History, and Prostate Cancer Incidence in an East Algerian Patient Group. Biomed. Res. Int. 2016, 2016.
  89. Bashir, M.N.; Ahmad, M.R.; Malik, A. Risk factors of prostate cancer: A case-control study in Faisalabad, Pakistan. Asian Pac. J. Cancer Prev. 2014, 15, 10237–10240.
  90. Shahabi, A.; Corral, R.; Catsburg, C.; Joshi, A.D.; Kim, A.; Lewinger, J.P.; Koo, J.; John, E.M.; Ingles, S.A.; Stern, M.C. Tobacco smoking, polymorphisms in carcinogen metabolism enzyme genes, and risk of localized and advanced prostate cancer: Results from the California Collaborative Prostate Cancer Study. Cancer Med. 2014, 3, 1644–1655.
  91. Watters, J.L.; Park, Y.; Hollenbeck, A.; Schatzkin, A.; Albanes, D. Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2427–2435.
  92. Jones, M.R.; Joshu, C.E.; Kanarek, N.; Navas-Acien, A.; Richardson, K.A.; Platz, E.A. Cigarette smoking and prostate cancer mortality in four US States, 1999–2010. Prev. Chronic. Dis. 2016, 13, E51.
  93. Wilson, K.M.; Markt, S.C.; Fang, F.; Nordenvall, C.; Rider, J.R.; Ye, W.; Adami, H.O.; Stattin, P.; Nyrén, O.; Mucci, L.A. Snus use, smoking and survival among prostate cancer patients. Int. J. Cancer 2016, 139, 2753–2759.
  94. Hálfdánarson, Ó.; Fall, K.; Ogmundsdottir, M.H.; Lund, S.H.; Steingrímsson, E.; Ogmundsdottir, H.M.; Zoega, H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study. Pharmacoepidemiol. Drug Saf. 2019, 28, 471–478.
  95. Nielsen, S.F.; Nordestgaard, B.G.; Bojesen, S.E. Statin Use and Reduced Cancer-Related Mortality. N. Engl. J. Med. 2012, 367, 1792–1802.
  96. Sarkar, R.R.; Parsons, J.K.; Bryant, A.K.; Ryan, S.T.; Kader, A.K.; McKay, R.R.; D’Amico, A.V.; Nguyen, P.L.; Hulley, B.J.; Einck, J.P.; et al. Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern. Med. 2019, 179, 812–819.
  97. Harris, A.M.; Warner, B.W.; Wilson, J.M.; Becker, A.; Rowland, R.G.; Conner, W.; Lane, M.; Kimbler, K.; Durbin, E.B.; Baron, A.T.; et al. Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study. J. Urol. 2007, 178, 2176–2180.
  98. Strand, D.S.; Kim, D.; Peura, D.A. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver 2017, 11, 27–37.
  99. Sachs, G.; Shin, J.M.; Howden, C.W. Review article: The clinical pharmacology of proton pump inhibitors. Aliment. Pharm. Ther. 2006, 23, 2–8.
  100. Schneider, L.S.; Schwarzenberg KVon Lehr, T.; Ulrich, M.; Liebl, J.; Trauner, D.; Menche, D.; Vollmar, A.M. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer. Ther. Targets Chem. Biol. 2015, 75, 2863–2875.
  101. Michel, V.; Licon-munoz, Y.; Trujillo, K.; Bisoffi, M.; Parra, K.J. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int. J. Cancer 2013, 132, E1–E10.
  102. De Milito, A.; Canese, R.; Marino, M.L.; Borghi, M.; Iero, M.; Villa, A.; Venturi, G.; Lozupone, F.; Iessi, E.; Logozzi, M.; et al. pH-dependent antitumor activity of proton pump inhibitorsagainst human melanoma is mediated by inhibition oftumor acidity. Int. J. Cancer 2010, 127, 207–219.
  103. Goldberg, H.; Mohsin, F.K.; Kulkarni, G.S.; Berlin, A.; Kenk, M.; Wallis, C.J.D.; Chandrasekar, T.; Klaassen, Z.; Saarela, O.; Penn, L.; et al. The deleterious association between proton pump inhibitors and prostate cancer-specific mortality—A population-based cohort study. Prostate Cancer Prostatic Dis. 2018, 28, 471–478.
  104. Eisenberg, D.A. Cholesterol Lowering in the Management of Coronary Artery Disease: The Clinical Implications of Recent Trials. Am. J. Med. 1998, 104, 2S–5S.
  105. Larsen, S.B.; Dehlendorff, C.; Skriver, C.; Dalton, S.O.; Gade, C.; Borre, M.; Brasso, K.; Nørgaard, M.; Johansen, C.; Sørensen, H.T.; et al. Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. J. Clin. Oncol. 2019, 35, 3290–3296.
  106. Rompay MIVan Solomon, K.R.; Nickel, J.C.; Ranganathan, G.; Kantoff, P.W.; Mckinlay, J.B. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur. J. Cancer 2019, 112, 118–126.
  107. Doat, S.; Cénée, S.; Trétarre, B.; Rebillard, X.; Lamy, P.J.; Bringer, J.P.; Iborra, F.; Murez, T.; Sanchez, M.; Menegaux, F. Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: Results from the EPICAP study. Cancer Med. 2017, 6, 2461–2470.
  108. Knights, K.M.; Mangoni, A.A.; Miners, J.O. Defining the COX inhibitor selectivity of NSAIDs: Implications for understanding toxicity. Expert. Rev. Clin. Pharmacol. 2010, 3, 769–776.
  109. Ma, Y.; Brusselaers, N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis. 2018, 21, 147–152.
  110. Shang, Z.; Wang, X.; Yan, H.; Cui, B.; Wang, Q.; Wu, J.; Cui, X.; Li, J.; Ou, T.; Yang, K. Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A meta-analysis. Front. Oncol. 2018, 8, 437.
  111. Andriole, G.L.; Guess, H.A.; Epstein, J.I.; Wise, H.; Kadmon, D.; Crawford, E.D.; Hudson, P.; Jackson, C.L.; Romas, N.A.; Patterson, L.; et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. J. Urol. 1999, 161, 195–202.
  112. Unger, J.M.; Hershman, D.L.; Till, C.; Tangen, C.M.; Barlow, W.E.; Ramsey, S.D.; Goodman, P.J.; Thompson, I.M. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2018, 110, 1208–1215.
  113. Wallerstedt, A.; Strom, P.; Gronberg, H.; Nordstrom, T.; Eklund, M. Risk of prostate cancer in men treated with 5a-reductase inhibitors-a large population-based prospective study. J. Natl. Cancer Inst. 2018, 110, 1216–1221.
  114. Wu, Y.; Wang, Y.; Gu, Y.; Xia, J.; Qian, Q.; Hong, Y. Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis. Urology 2020, 145, 216–223.
  115. Walden, P.D.; Durkin, M.M.; Lepor, H.; Wetzel, J.M.; Gluchowski, C.; Gustafson, E.L. Localization of mRNA and receptor binding sites for the α(1a)- adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J. Urol. 1997, 157, 1032–1038.
  116. McConnell, J.D.; Roehrborn, C.G.; Bautista, O.M.; Andriole, G.L., Jr.; Dixon, C.M.; Kusek, J.W.; Lepor, H.; McVary, K.T.; Nyberg, L.M., Jr.; Clarke, H.S.; et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N. Engl. J. Med. 2003, 349, 2387–2398.
  117. Hart, J.; Spencer, B.; McDermott, C.M.; Chess-Williams, R.; Sellers, D.; Christie, D.; Anoopkumar-Dukie, S. A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy. Sci. Rep. 2020, 10, 8191.
  118. Taylor, M.L.; Mainous, A.G.; Wells, B.J. Prostate Cancer and Sexually Transmitted Diseases: A Meta-analysis. Fam. Med. 2005, 37, 506–512.
  119. Wolitski, R.J.; Fenton, K.A. Sexual Health, HIV, and Sexually Transmitted Infections among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States. AIDS Behav. 2011, 15, 9–17.
  120. Wang, J.; Häusermann, M.; Vounatsou, P.; Aggleton, P.; Weiss, M.G. Health status, behavior, and care utilization in the Geneva Gay Men’s Health Survey. Prev. Med. 2007, 44, 70–75.
  121. Rider, J.R.; Wilson, K.M.; Sinnott, J.A.; Kelly, R.S.; Mucci, L.A.; Giovannucci, E.L. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur. Urol. 2016, 70, 974–982.
  122. Papa, N.P.; Macinnis, R.J.; English, D.R.; Bolton, D.; Davis, I.D.; Lawrentschuk, N.; Millar, J.L.; Pederson, J.; Severi, G.; Southey, M.C.; et al. Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Urol. Oncol. Semin. Orig. Investig. 2017, 35, 530.e7–530.e13.
  123. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62:55–62. https://doi.org/10.1016/j.urology.2003.09.053.
  124. Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. Cancers (Basel) 2020;12:1–24. https://doi.org/10.3390/cancers12102984.
  125. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–69. https://doi.org/10.1038/nrc2090.
  126. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative Inflammatory Atrophy of the Prostate Implications for Prostatic Carcinogenesis. Am J Pathol 1999;155:1985–92. https://doi.org/10.1016/S0002-9440(10)65517-4.
  127. Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 2018;15:11–24. https://doi.org/10.1038/nrurol.2017.167.
  128. Rani A, Dasgupta P, Murphy JJ. Prostate Cancer: the role of inflammation and chemokines. Am J Pathol 2019;189:2119–37. https://doi.org/10.1016/j.ajpath.2019.07.007
  129. Ugge H, Downer MK, Carlsson J, Bowden M, Davidsson S, Mucci LA, et al. Circulating inflammation markers and prostate cancer. Prostate 2019;79:1338–46. https://doi.org/10.1002/pros.23842.
  130. Hendriks RJ, Van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: A review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20:12–9. https://doi.org/10.1038/pcan.2016.59
  131. Truong M, Yang B, Jarrard DF. Toward the Detection of Prostate Cancer in Urine: A Critical Analysis. J Urol 2013;189:422–9. https://doi.org/10.1016/j.juro.2012.04.143.
  132. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014;6:74–7. https://doi.org/10.1177/1756287213513488.
  133. Kok JB De, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3 (PCA3), a Very Sensitive and Specific Marker to Detect Prostate Tumors. Cancer Res 2002;62:2695–8.
  134. Salagierski M, Schalken JA. Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2: ERG Gene Fusion. J Urol 2012;187:795–801. https://doi.org/10.1016/j.juro.2011.10.133
  135. Scattoni V, Lazzeri M, Lughezzani G, Luca S De, Passera R, Bollito E, et al. Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy. J Urol 2013;190:496–501. https://doi.org/10.1016/j.juro.2013.02.3184.
  136. Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012;413:1274–8. https://doi.org/10.1016/j.cca.2012.04.017.
  137. Seisen T, Rouprêt M, Brault D, Priscilla L. Accuracy of the Prostate Health Index Versus the Urinary Prostate Cancer Antigen 3 Score to Predict Overall and Significant Prostate Cancer at Initial Biopsy. Prostate 2015;75:103–11. https://doi.org/10.1002/pros.22898
  138. Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, Perruolo G, et al. Improving the Prediction of Pathologic Outcomes in Patients Undergoing Radical Prostatectomy: The Value of Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (PHI) and Sarcosine. Anticancer Res 2015;35:1017–23.
  139. Cantiello F, Ph D, Russo GI, D M, Ferro M, D M, et al. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. Urol Oncol Semin Orig Investig 2015;33:163.e15-163.e23. https://doi.org/10.1016/j.urolonc.2014.12.002
  140. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008;6:1–10. https://doi.org/10.1186/1741-7015-6-19
  141. Szeliski K, Adamowicz J, Gastecka A, Drewa T, Pokrywczyńska M. Modern urology perspectives on prostate cancer biomarkers. Cent Eur J Urol 2018;71:420–6. https://doi.org/10.5173/ceju.2018.1762.
  142. Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med 2020;58:326–39. https://doi.org/10.1515/cclm-2019-0693
  143. Yang B, Zhang C, Cheng S, Li G, Griebel J, Neuhaus J. Novel Metabolic Signatures of Prostate Cancer Revealed by 1 H-NMR Metabolomics of Urine. Diagnostics 2021;11:1–18. https://doi.org/10.3390/diagnostics11020149.
  144. Lima T, Ferreira R, Freitas M, Henrique R, Vitorino R, Fardilha M. Integration of Automatic Text Mining and Genomic and Proteomic Analysis to Unravel Prostate Cancer Biomarkers. J Proteome Res 2022;21:447–58. https://doi.org/10.1021/acs.jproteome.1c00763
  145. Felgueiras J, Silva JV, Nunes A, Fernandes I, Patrício A, Maia N, et al. Investigation of spectroscopic and proteomic alterations underlying prostate carcinogenesis. J Proteomics 2020;226:103888. https://doi.org/10.1016/j.jprot.2020.103888
  146. Santos F, Magalhães S, Henriques MC, Silva B, Valença I, Ribeiro D, et al. Understanding Prostate Cancer Cells Metabolome: A Spectroscopic Approach. Curr Metabolomics 2018;6:218–24. https://doi.org/10.2174/2213235x07666181122124106
  147. Xu H, Chen J, He J, Ji J, Cao Z, Chen X, et al. Serum Metabolic Profiling Identifies a Biomarker Panel for Improvement of Prostate Cancer Diagnosis. Front Oncol 2021;11:1–9. https://doi.org/10.3389/fonc.2021.666320
  148. Mckiernan J, Donovan MJ, Neill VO, Bentink S, Noerholm M, Belzer S, et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol 2016;2:882–9. https://doi.org/10.1001/jamaoncol.2016.0097.
  149. Munson P, Shukla A. Exosomes: Potential in Cancer Diagnosis and Therapy. Medicines 2015;2:310–27. https://doi.org/10.3390/medicines2040310
  150. Tian H, Liu X, Han W, Zhao L-L, Yuan B, Yuan C-J. Differential expression of filamin A and its clinical significance in breast cancer. Oncol Lett 2013;6:681–6. https://doi.org/10.3892/ol.2013.1454
  151. Weinstein SJ, Stolzenberg-solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D. Impact of Circulating Vitamin D Binding Protein Levels on the Association between 25-Hydroxyvitamin D and Pancreatic Cancer Risk: A Nested Case – Control Study. Cancer Res 2012;72:1190–9. https://doi.org/10.1158/0008-5472.CAN-11-2950
  152. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, et al. Afamin and Apolipoprotein A-IV : Novel Protein Markers for Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127–34. https://doi.org/10.1158/1055-9965.EPI-08-0653
  153. Black OM, Singh R, Mercer R, Bokhoven A Van, Torkko KC, Agarwal C, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med 2019;8:1110–23. https://doi.org/10.1002/cam4.1885
  154. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029–33. https://doi.org/10.1158/0008-5472.CAN-05-0137.
  155. Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010;31:867–73. https://doi.org/10.1038/aps.2010.48.
  156. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348–60. https://doi.org/10.1261/rna.1034808.
  157. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008;12:2171–6. https://doi.org/10.1007/s11605-008-0584-x
  158. Dong B, Shi Z, Wang J, Wu J, Yang Z, Fang K. IL-6 inhibits the targeted modulation of PDCD4 by miR-21 in prostate cancer. PLoS One 2015;10:1–10. https://doi.org/10.1371/journal.pone.0134366
  159. Liu R, Li J, Teng Z, Zhang Z, Xu Y. Overexpressed MicroRNA-182 Promotes Proliferation and Invasion in Prostate Cancer PC-3 Cells by Down-Regulating N-myc Downstream Regulated Gene 1 (NDRG1). PLoS One 2013;8:1–10. https://doi.org/10.1371/journal.pone.0068982.
  160. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166–76. https://doi.org/10.1002/ijc.24827.
  161. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, et al. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 2011;286:44503–11. https://doi.org/10.1074/jbc.M111.262915.
  162. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer. PLoS One 2013;8:1–12. https://doi.org/10.1371/journal.pone.0055502
  163. Minegishi M, Kuchimaru T, Nakagawa K, Isozaki T, Fujimori S, Kadonosono T, et al. Multiplexed bioluminescence imaging of cancer cell response to hypoxia and inflammation in the caudal-artery injection model of bone metastasis during zoledronic acid treatment. J Cancer Metastasis Treat 2021;7:1–12. https://doi.org/10.20517/2394-4722.2020.96.
  164. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: an overview. Oncol Rev 2017;11:321–8. https://doi.org/10.4081/oncol.2017.321.
  165. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, et al. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009;119:1093–108. https://doi.org/10.1172/JCI35079
  166. Li Y, Zhang D, Wang X, Yao X, Ye C, Zhang S, et al. Hypoxia-inducible MIR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer. Sci Rep 2015;5:1–13. https://doi.org/10.1038/srep12495
  167. Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, et al. miRNAs associated with prostate cancer risk and progression. BMC Urol 2017;17:1–18. https://doi.org/10.1186/s12894-017-0206-6
  168. Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT, et al. Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res 2011;4:1073–83. https://doi.org/10.1158/1940-6207.CAPR-10-0333
  169. Kim Y, Jeon Y, Lee H, Lee D, Shim B. The prostate cancer patient had higher C-reactive protein than BPH patient. Korean J Urol 2013;54:85–8. https://doi.org/10.4111/kju.2013.54.2.85.
  170. Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 2011;9:1–9. https://doi.org/10.1186/1479-5876-9-162.
  171. Aroke D, Folefac E, Shi N, Jin Q, Clinton SK, Tabung FK. Inflammatory and insulinemic dietary patterns: Influence on circulating biomarkers and prostate cancer risk. Cancer Prev Res 2020;13:841–52. https://doi.org/10.1158/1940-6207.CAPR-20-0236
  172. Tabung FK, Wang W, Fung TT, Hu FB, Smith-Warner SA, Chavarro JE, et al. Development and validation of empirical indices to assess the insulinaemic potential of diet and lifestyle. Br J Nutr 2016;116:1787–98. https://doi.org/10.1017/S0007114516003755
  173. Tabung FK, Smith-Warner SA, Chavarro JE, Wu K, Fuchs CS, Hu FB, et al. Development and validation of an empirical dietary inflammatory index. J Nutr 2016;146:1560–70. https://doi.org/10.3945/jn.115.228718
  174. Aydin S, Kuloglu T, Ozercan MR, Albayrak S, Aydin S, Bakal U, et al. Irisin immunohistochemistry in gastrointestinal system cancers. Biotech Histochem 2016;91:242–50. https://doi.org/10.3109/10520295.2015.1136988.
  175. Zhu H, Liu M, Zhang N, Pan H, Lin G, Li N, et al. Serum and adipose tissue mRNA levels of ATF3 and FNDC5/irisin in colorectal cancer patients with or without obesity. Front Physiol 2018;9:1–10. https://doi.org/10.3389/fphys.2018.01125
  176. Aslan R, Alp HH, Eryılmaz R, Huyut Z, Sevim M, Araz S, et al. Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study. Asian Pacific J Cancer Prev 2020;21:505–9. https://doi.org/10.31557/APJCP.2020.21.2.505.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Catarina Leitão
,
Bárbara Matos
,
Fátima Roque
,
Maria Teresa Herdeiro
,
Margarida Fardilha
View Times: 714
Revisions: 3 times (View History)
Update Date: 31 May 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback